Below are 3 of the clinical trials Novo Nordisk completed for Xultophy® 100/3.6, a combination of insulin degludec and liraglutide.
Once-daily Xultophy® 100/3.6 is FDA approved!
Xultophy® 100/3.6 is a combination of insulin degludec and liraglutide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 50 units daily) or liraglutide (less than or equal to 1.8 mg daily).
See the Xultophy® 100/3.6 clinical studies
aSome data points presented in the study results may not be an exact match to the number listed in the Prescribing Information. This is due to a difference in statistical methodologies.
Get the latest on Xultophy® 100/3.6, available in pharmacies soon
Sign up to receive updates on this new treatment for adults with type 2 diabetes! You will also gain access to the resources of NovoMedLink™, the 24/7 support portal for your practice.